June 2022

The Column Group Raises $1.23 Billion in Two New Funds

We are very excited to announce that we have closed the two newest funds of the TCG fund family – The Column Group V (“TCG V”), a $615 million fund focused on early-stage investments, and The Column Group Opportunity III (“TCG Opportunity III”), also $615 million but focused on later stage investments in our companies. …

The Column Group Raises $1.23 Billion in Two New Funds Read More »

NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

The Column Group Raises $1.23 Billion in Two New Funds

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity